A STUDY TO INVESTIGATE THE TOLERABILITY OF SUBCUTANEOUS (SC) TRASTUZUMAB ADMINISTRATION IN PARTICIPANTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) POSITIVE EARLY BREAST CANCER (EBC) USING EITHER A SINGLE-USE INJECTION DEVICE OR MANUAL ADMINISTRATION: